Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-076-7 | CAS number: 51-03-6
Exposure related observations in humans: other data
Administrative data
- Endpoint:
- exposure-related observations in humans: other data
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1972
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- review article or handbook
- Title:
- Effects of Piperonyl butoxide on drug metabolism in rodents and man
- Author:
- Conney, A.H., Chang, R., Levin, W.M., Garbut, A., Munro-Faure, A.D., Peck, A.W., Bye, A.
- Year:
- 1 972
- Bibliographic source:
- Arch. Env. Health 24, 97-106.
Materials and methods
- Type of study / information:
- Type of experience: Human
- Endpoint addressed:
- basic toxicokinetics
- GLP compliance:
- no
Test material
- Reference substance name:
- 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether
- EC Number:
- 200-076-7
- EC Name:
- 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether
- Cas Number:
- 51-03-6
- Molecular formula:
- C19H30O5
- IUPAC Name:
- 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether
Constituent 1
Results and discussion
- Results:
- No adverse effects were reported.The mean half-life of antipyrine was not influenced. There was no evidence that an oral dose of 50 mg Piperonyl Butoxide in humans has any effect on the metabolism of antipyrine in humans.
Applicant's summary and conclusion
- Conclusions:
- No adverse effects were reported.The mean half-life of antipyrine was not influenced. There was no evidence that an oral dose of 50 mg Piperonyl Butoxide in humans has any effect on the metabolism of antipyrine in humans.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
